Search

Displaying results 2081 - 2090 of 10000 in total
  1. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    [A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin … [A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia.

    Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-
  2. Drug

    Penicillamine

    go.drugbank.com/drugs/DB00859
    ApprovedInvestigational

    Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). … It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the … Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label].

    Products: IVABRADIN AL 5MG, IVABRADIN AL 7.5MG
  4. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    [L39774] The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases, … [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,

  5. Drug

    Bromotheophylline

    go.drugbank.com/drugs/DB14018
    Approved

    [L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.

  6. Drug

    Abiraterone

    go.drugbank.com/drugs/DB05812
    ApprovedInvestigational

    Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis … [L40968, L40193, L47740, L47745] and when used in combination with niraparib, BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).

    Products: Abirateron 1A Pharma 500 mg - Filmtabletten, Abirateron 1A Pharma 1000 mg – Filmtabletten
  7. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261] … Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan].

  8. Drug

    Phosphorus

    go.drugbank.com/drugs/DB14151
    Approved

    Mixtures: Vc II, Multipack II
  9. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA. … It is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of α-glucosidase (GAA).

  10. Drug

    Cetuximab sarotalocan

    go.drugbank.com/drugs/DB19240
    Investigational

    Cetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy